Brought to you by 
Merck, Alnylam end RNAi agreement for ophthalmic drugs
Jul 2004
Executive Summary
Merck & Co. and Alnylam Pharmaceuticals (therapeutics based on RNA interference) have signed a multi-year agreement covering the development and marketing of RNAi drugs (particularly VEGF inhibitors) to treat ocular diseases.
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Equity
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck, Alnylam end RNAi agreement for ophthalmic drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice